G9837 HCPCS Level II code: Trastuzumab not administered within 12 months of diagnosis
CMS terminated G9837: its last date of service was Dec 31, 2020. It stays here for looking up older claims; newer services need a current code.
Official description
G9837Trastuzumab not administered within 12 months of diagnosis
Short description: Trastuz not in 12 mos dx
HCPCS · United States
Medicare details
The indicators CMS publishes with G9837 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care
- BETOS category
- Undefined codes
- Added
- Jan 1, 2017
- Terminated after
- Dec 31, 2020
Where G9837 sits
- 1G codesProcedures and professional services
- 2Terminated G9837Trastuzumab not administered within 12 months of diagnosis
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code G9837 still valid?
No. CMS terminated G9837; its last date of service was Dec 31, 2020. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover G9837?
CMS lists G9837’s Medicare coverage as “Carrier judgment” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside G9837
All G codesG9831Ajcc stage at breast cancer diagnosis = ii or iiiG9832Ajcc stage at breast cancer diagnosis = i (ia or ib) and t-stage at breast cancer diagnosis = t1cG9833Patient transfer to practice after initiation of chemotherapyG9834Patient has metastatic disease at diagnosisG9835Trastuzumab administered within 12 months of diagnosisG9836Reason for not administering trastuzumab documented (e.g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant…G9838Patient has metastatic disease at diagnosisG9839Anti-egfr monoclonal antibody therapyG9840Ras (kras and nras) gene mutation testing performed before initiation of anti-egfr moabG9841Ras (kras and nras) gene mutation testing not performed before initiation of anti-egfr moabG9842Patient has metastatic disease at diagnosisG9843Ras (kras or nras) gene mutation